Benign prostatic hyperplasia: Racial differences in treatment patterns and prostate cancer prevalence

BJU International

Volumn 108, Issue 8, 2011, Pages 1302-1308

  Pettaway, Curtis A ^a   Lamerato, Lois E ^b   Eaddy, Michael T ^c   Edwards, Jessie K ^d   Hogue, Susan L ^d   Crane, Martin M ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c XCENDA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

acute urinary retention; benign prostatic hyperplasia; lower urinary tract symptoms; prostate cancer

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACUTE DISEASE; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AFRICAN AMERICANS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY RETENTION;

EID: 80053383916     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09991.x     Document Type: Article

References (25)

1. Issa M, Fenter T, Black L, Grogg A, Kruep E,. An assessment of the diagnosed prevalence of diseases in men 50 years of age and older. Am J Manag Care 2006; 12 (4 Suppl.): S83-9
2. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61 (Pubitemid 40380548)
3. Naslund MJ, Chiao E, Black L, Eaddy MT,. The hidden condition: status, challenges, and opportunities in the management of enlarged prostate for managed care. Am J Manag Care 2006; 12 (4 Suppl.): S76-82
4. Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L,. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 2006; 12 (4 Suppl.): S111-6
5. Black L, Naslund MJ, Gilbert TD Jr, Davis EA, Ollendorf DA,. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006; 12 (4 Suppl.): S99-110
6. Issa MM, Regan TS,. Medical therapy for benign prostatic hyperplasia-present and future impact. Am J Manag Care 2007; 13 (Suppl. 1): S4-9
7. Nickel JC,. BPH: costs and treatment outcomes. Am J Manag Care 2006; 12 (5 Suppl.): S141-8
8. Sarma AV, McLaughlin JC, Jacobsen SJ, et al,. Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. Urology 2004; 64: 959-65 (Pubitemid 39469514)
9. Howard DL, Taylor YJ, Ross LE,. Differences in lower urinary tract symptoms, treatment and mortality among African-American and white elderly men. J Natl Med Assoc 2008; 100: 1146-52
10. Chute CG, Panser LA, Girman CJ, et al,. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9 (Pubitemid 23175978)
11. Wei JT, Schottenfeld D, Cooper K, et al,. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001; 165: 1521-5 (Pubitemid 32410229)
12. Gee WF, Holtgrewe HL, Blute ML, et al,. 1997 American Urological Association Gallup Survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 1998; 160: 1804-7 (Pubitemid 128746765)
13. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E,. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009-17 (Pubitemid 32045897)
14. Jemal A, Siegal R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer Statistics 2009. CA Cancer J Clin 2009; 59: 225-49
15. Thompson IM, Goodman PJ, Tangen CM, et al,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24 (Pubitemid 36859473)
16. Kim CI, Chang HS, Kim BK, Park CH,. Long-term results of medical treatment in benign prostatic hyperplasia. Urology 2006; 68: 1015-9 (Pubitemid 44750136)
17. Glynn RJ, Campion EW, Bouchard GR, Silbert JE,. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90 (Pubitemid 15150691)
18. Jacobsen SJ, Jacobson DJ, Girman CJ, et al,. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999; 162: 1301-6 (Pubitemid 29428567)
19. Joseph MA, Harlow SD, Wei JT, et al,. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157: 906-14 (Pubitemid 36555050)
20. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S,. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53 (Pubitemid 47036593)
21. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41 (Pubitemid 35292169)
22. Roehrborn CG, Siami P, Barkin J, et al,. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21
23. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
24. Schroder FH, Roobol MJ, Andriole GL, Fleshner N,. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 2009; 181: 69-74
25. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8